Genetic determinants of plasma triglycerides
Key result
Genetic variation at loci identified by genome-wide association studies explains only 10% of overall plasma triglyceride variation within the population.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Current GWAS loci offer minimal clinical utility for TG risk assessment; leaves open rare variant sequencing to identify therapeutic targets.
Key Points
- The research aims to identify genetic determinants influencing plasma triglyceride (TG) concentrations and their implications for cardiovascular disease risk.
- Conducted genome-wide association studies (GWAS) to identify loci associated with plasma TG concentration.
- Reviewed recent findings on genes implicated in TG metabolism and their effects on plasma TG levels.
- Evaluated alternative genetic approaches for a more comprehensive understanding of TG metabolism.
- Identified both known and novel loci associated with plasma TG concentration; however, they account for only 10% of overall TG variation in the population.
- Proposed that alternative approaches, like rare variant sequencing and animal models, may clarify important pathways in TG metabolism.
- Discussed challenges in treating patients with hypertriglyceridemia, emphasizing potential new therapeutic strategies from genetic findings.
PICO
P
Population
Hypertriglyceridemia
E
Exposure / Comparator
Genetic variation
This review highlights that while GWAS has identified loci associated with plasma triglycerides, they explain only a small fraction of variation, underscoring the need for alternative genetic strategies to identify therapeutic targets for hypertriglyceridemia.
Cite This Study
Johansen et al. (2010) conducted a review in Hypertriglyceridemia. Genetic variation was evaluated. Genetic variation at loci identified by genome-wide association studies explains only 10% of overall plasma triglyceride variation within the population.